| 1.2 0.19 (18.81%) | 05-20 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 1.46 |
1-year : | 1.7 |
| Resists | First : | 1.25 |
Second : | 1.46 |
| Pivot price | 1.07 |
|||
| Supports | First : | 1.07 |
Second : | 0.97 |
| MAs | MA(5) : | 1.05 |
MA(20) : | 1.07 |
| MA(100) : | 1.66  |
MA(250) : | 2.23 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 32.9 |
D(3) : | 19.2 |
| RSI | RSI(14): 57.7 |
|||
| 52-week | High : | 8.22 | Low : | 0.83 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ ALZN ] has closed above the upper band by 11.9%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 64.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 23 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.25 - 1.26 | 1.26 - 1.27 |
| Low: | 0.99 - 0.99 | 0.99 - 1 |
| Close: | 1.19 - 1.2 | 1.2 - 1.21 |
Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001 that is in Phase II clinical trial, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and AL002 that completed preclinical stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.
Mon, 20 Apr 2026
Alzamend (ALZN) Stock Swing Trade Setup (On the Radar) 2026-04-20 - Sector Rotation - Cổng thông tin điện tử tỉnh Lào Cai
Sat, 18 Apr 2026
Alzamend Neuro Shareholders Approve Governance and Capital Measures - The Globe and Mail
Fri, 17 Apr 2026
Shareholders of Alzamend Neuro (ALZN) approve board slate, plans and reverse split - Stock Titan
Thu, 26 Mar 2026
Alzamend’s AL001 meets bioequivalence in phase 2 brain trial - Investing.com
Thu, 26 Mar 2026
Across 26 brain regions, Alzamend’s lithium drug showed higher levels - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 4 (M) |
| Shares Float | 4 (M) |
| Held by Insiders | 0.5 (%) |
| Held by Institutions | 3 (%) |
| Shares Short | 205 (K) |
| Shares Short P.Month | 326 (K) |
| EPS | -3.68 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.56 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -107.1 % |
| Return on Equity (ttm) | -250 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.83 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -6 (M) |
| Levered Free Cash Flow | -4 (M) |
| PE Ratio | -0.33 |
| PEG Ratio | 0 |
| Price to Book value | 2.1 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.77 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|